Weight loss medication Wegovy may soon be cheaper for thousands of people after the Pharmaceutical Benefits Advisory ...

Healthcare stocks haven't gotten a lot of love from investors in recent years. While the market has been strong and the S&P ...

Sacramento Telehealth Company Positions Multi-Form Compounded Semaglutide Access Through Licensed Medical Providers Ahead of ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...